AN2 Therapeutics Stock Plummets On Decision To Pause Enrollment In Epetraborole Phase 2/3 Trial
12/2 13:08
(RTTNews) - AN2 Therapeutics, Inc. (ANTX) announced the company's decision to voluntarily pause Phase 3 enrollment in the Phase 2/3 clinical trial evaluating epetraborole in treatment-refractory MAC lung disease, pending further data review. The decision was based on a blinded ag...